Support for establishing the Therapy Acceleration Laboratory in Oxford to assess clinical trial samples (back translation)

点击翻译按钮获取中文摘要

The Therapy Acceleration Laboratory would: a) Set world-leading standards in quality and impact to study samples, using specialist genetic, immunological, phenotypic and pathological assays, from clinical trials to accelerate therapy development, including supporting registrational trials in partnership with academics, the NHS and industry. b) Enable discovery and application that open new areas of biology with mechanistic studies developed using state-of-the-art technologies and methods.c) Utilise strengths and capability across the UK, and the international biomedical landscape, to attract the most innovative clinical trials with the potential to rapidly transform human health.Of note, there are already three academically sponsored Phase III registrational trials in advanced negotiation due to start between October and December 2021 that would be supported by the TAL. The beneficiaries: would be patients, the three partner MRC Units, the NHS, other academic units throughout the UK, the NHS and industry.